Larry Harshyne

6PUBLICATIONS
77CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSpeciation and extinction
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 03, 2026
Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy.

|Dec 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.

Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson

|Sep 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.

Pablo Llerena, Hani Samarah, Kathryn Nunes

|Nov 25, 2024
Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma.

Eric V Mastrolonardo, Kathryn L Nunes, Pablo Llerena

|Oct 10, 2024
Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis.

Priyan Bhattacharya, Alban Linnenbach, Andrew P South

|Mar 09, 2021
Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts.

Michael Prosniak, Larry A Harshyne, Jonathan Gorky

Pageof 1

Frequent Collaborators

4 joint publications

Adam J Luginbuhl

4 joint publications

Athanassios Argiris

4 joint publications

Mỹ G Mahoney

4 joint publications

Joseph M Curry